Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Equity Ratio (2016 - 2025)

Historic Equity Ratio for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 0.53.

  • China Pharma Holdings' Equity Ratio rose 850.52% to 0.53 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53, marking a year-over-year increase of 850.52%. This contributed to the annual value of 0.52 for FY2024, which is 1497.64% up from last year.
  • Per China Pharma Holdings' latest filing, its Equity Ratio stood at 0.53 for Q3 2025, which was up 850.52% from 0.47 recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Equity Ratio peaked at 0.53 during Q3 2025, and registered a low of 0.17 during Q3 2022.
  • In the last 5 years, China Pharma Holdings' Equity Ratio had a median value of 0.38 in 2021 and averaged 0.38.
  • In the last 5 years, China Pharma Holdings' Equity Ratio tumbled by 5359.04% in 2022 and then soared by 12750.76% in 2023.
  • Quarter analysis of 5 years shows China Pharma Holdings' Equity Ratio stood at 0.27 in 2021, then fell by 9.21% to 0.24 in 2022, then skyrocketed by 87.64% to 0.45 in 2023, then increased by 14.98% to 0.52 in 2024, then rose by 1.08% to 0.53 in 2025.
  • Its Equity Ratio stands at 0.53 for Q3 2025, versus 0.47 for Q2 2025 and 0.49 for Q1 2025.